- Home
- FGMC vs LCTX Comparison
FGMC vs LCTX Comparison
Compare FGMC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGMC
- LCTX
- Stock Information
- Founded
- FGMC 2023
- LCTX 1990
- Country
- FGMC United States
- LCTX United States
- Employees
- FGMC N/A
- LCTX N/A
- Industry
- FGMC
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FGMC
- LCTX Health Care
- Exchange
- FGMC NYSE
- LCTX Nasdaq
- Market Cap
- FGMC 101.6M
- LCTX 119.9M
- IPO Year
- FGMC 2025
- LCTX N/A
- Fundamental
- Price
- FGMC $9.57
- LCTX $0.53
- Analyst Decision
- FGMC
- LCTX Strong Buy
- Analyst Count
- FGMC 0
- LCTX 4
- Target Price
- FGMC N/A
- LCTX $4.50
- AVG Volume (30 Days)
- FGMC 25.8K
- LCTX 1.1M
- Earning Date
- FGMC 01-01-0001
- LCTX 03-10-2025
- Dividend Yield
- FGMC N/A
- LCTX N/A
- EPS Growth
- FGMC N/A
- LCTX N/A
- EPS
- FGMC N/A
- LCTX N/A
- Revenue
- FGMC N/A
- LCTX $9,499,000.00
- Revenue This Year
- FGMC N/A
- LCTX $25.10
- Revenue Next Year
- FGMC N/A
- LCTX $35.67
- P/E Ratio
- FGMC N/A
- LCTX N/A
- Revenue Growth
- FGMC N/A
- LCTX 6.19
- 52 Week Low
- FGMC $4.48
- LCTX $0.48
- 52 Week High
- FGMC $9.85
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- FGMC N/A
- LCTX 37.73
- Support Level
- FGMC N/A
- LCTX $0.51
- Resistance Level
- FGMC N/A
- LCTX $0.58
- Average True Range (ATR)
- FGMC 0.00
- LCTX 0.05
- MACD
- FGMC 0.00
- LCTX -0.01
- Stochastic Oscillator
- FGMC 0.00
- LCTX 14.30
About FGMC FG MERGER II CORP
FG Merger II Corp is a blank check company.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.